HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Therapy and secondary prevention of venous thromboembolism with vitamin K antagonists].

Abstract
Oral anticoagulation with vitamin-K-antagonists is very effective in secondary prevention of venous thromboembolism. In Germany, most commonly Phenprocoumon is used, while most of the evidence-based data are available for Warfarin. The initial treatment of acute venous thromboembolism requires immediate anticoagulation with heparin and a subsequent overlapping treatment with oral anticoagulants. During this phase, anticoagulation may be unstable with increased risk for bleeding. An INR target range between 2 and 3 provides effective protection with minimal risk for major bleeding. The individual risk for bleeding may be estimated by a clinical score. Six months of oral anticoagulation is the standard duration for a first episode of venous thromboembolism, while recurrencies are treated for at least one to two years. The duration may be tailored to the individual patient according to underlying risk factors for recurrencies and for bleeding. Because of a plethora of practical problems and the narrow therapeutic window, there is a need for new antithrombotic agents. These may allow a longer duration of secondary prevention with improved protection against recurrencies without sacrificing safety.
AuthorsR M Bauersachs
JournalDer Internist (Internist (Berl)) Vol. 44 Issue 12 Pg. 1491-9 (Dec 2003) ISSN: 0020-9554 [Print] Germany
Vernacular TitleTherapie und Sekundärprophylaxe der venösen Thromboembolie mit Vitamin-K-Antagonisten.
PMID14689191 (Publication Type: English Abstract, Journal Article, Review)
Chemical References
  • Anticoagulants
  • Vitamin K
Topics
  • Administration, Oral
  • Anticoagulants (administration & dosage)
  • Clinical Trials as Topic
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Humans
  • Infant, Newborn
  • International Normalized Ratio
  • Male
  • Pregnancy
  • Pulmonary Embolism (blood, drug therapy, prevention & control)
  • Risk Factors
  • Secondary Prevention
  • Venous Thrombosis (blood, drug therapy)
  • Vitamin K (antagonists & inhibitors, blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: